Merial receives EU approval of Broadline parasiticide for cats

Merial has announced that the European Medicines Agency has approved Broadline, a product that offers broad spectrum parasite treatment and prevention in cats.

The topical feline endectocide combats external parasites while offering additional internal parasite control benefits for cats and kittens. It features a combination of four active ingredients and helps protect animals for one month.

It is approved for the treatment and prevention of flea and tick infestations, prevention of heartworm disease and treatment of roundworm, hookworm and tapeworm infestations in felines aged seven weeks and older.

Broadline was developed by Merial research centres in Europe and the US and has been proven safe and effective in extensive laboratory and clinical studies.

Carsten Hellmann, chief executive officer of Merial, said: "We are pleased to provide veterinarians with an all-in-one feline parasiticide that offers broad spectrum protection and is administered topically, which cat owners typically prefer."

One of the largest animal health companies in the world, Merial is a subsidiary of Sanofi and commands a global market share of more than 14 percent.